Niraparib Tosylate/Abiraterone Acetate

Tier C — Watch / trade

Jassen-Cilag International Nv

Originator

2023

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：PARP-2, PARP1, CYP17A1

Brand：AKEEGA

Indications (approved)：Hormone-sensitive prostate cancer, Castration-resistant prostate cancer

Regional status

Approved

2023-08-11

Approved

2023-04-19

China

Approved

2024-10-16

Japan

Factories producing this API16

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

16 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Niraparib Tosylate/Abiraterone Acetate?

Approved indications include: Hormone-sensitive prostate cancer, Castration-resistant prostate cancer.

When does the Niraparib Tosylate/Abiraterone Acetate patent expire?

No public expiry year is available for Niraparib Tosylate/Abiraterone Acetate yet; this page updates once verified.

How do I get a quote for Niraparib Tosylate/Abiraterone Acetate intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27